Screening for Prostate Cancer: PSA: Why 1.5 is the New 4.0
E. David Crawford, MD, argues for using PSA levels of 1.5 ng/mL as the cutoff point for determining prostate cancer risk in routine screening. He discusses the need for utilizing better risk-assessment methods for detecting prostate cancer, such as genomic markers, in order to reduce unnecessary biopsies, over-detection of indolent disease, and reliance on PSA testing alone.
Read More